Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) . Datopotamab deruxtecan has a potent antitumor activity.
[accordions]
[accordion title= “Biological Description“]
Description | Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) . Datopotamab deruxtecan has a potent antitumor activity. |
In vitro | Datopotamab deruxtecan (Dato-DXd; 100 μg/mL) binds specifically to TROP2 and was internalized into tumor cells followed by intracellular trafficking to lysosome and Deruxtecan release, which induced DNA damage and apoptosis in TROP2-expressing tumor cells in vitro[1]. |
In vivo | Datopotamab deruxtecan (Dato-DXd; 6 mg/kg) shows potent antitumor activity with tumor regression in several TROP2-expressing xenograft tumors including NSCLC patient-derived xenograft (PDX) models. Safety profiles of Datopotamab deruxtecan in rats and cynomolgus monkeys are acceptable[1]. |
[/accordion]
[accordions]
[accordion title= “Chemical Properties“]
Synonyms | DS-1062, Dato-DXd |
Molecular Weight | N/A |
CAS No. | 2238831-60-0 |
[/accordion]
[accordions]
[accordion title= “References and Literature“]
[/accordion]